ReviewChemistry, an Asian journal2025
Advances in Small Molecule Inhibitors Targeting the Bacterial Lipoprotein Transport System (Lol) in Gram-Negative Bacteria.
Review in Chemistry, an Asian journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic Evaluation of LolA andInternational journal of microbiology · 2026Article
- Protein-Protein Interactions as Promising Molecular Targets for Novel Antimicrobials Aimed at Gram-Negative Bacteria.International journal of molecular sciences · 2025Review
- Advances in Small Molecule Inhibitors Targeting the Bacterial Lipoprotein Transport System (Lol) in Gram-Negative Bacteria.Chemistry, an Asian journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The escalating threat of antimicrobial resistance (AMR) necessitates the urgent development of novel antibiotics, particularly those against multidrug-resistant gram-negative bacteria. These pathogens possess formidable structural defenses, including an impermeable outer membrane (OM) and robust efflux pumps, which hinder antibiotic efficacy. A promising therapeutic target is the lipoprotein transport system (Lol), which is essential for bacterial viability. The LolABCDE complex ensures the precise localization of lipoproteins, which is crucial for maintaining outer membrane integrity and cell survival. Disruption of this system results in severe structural and functional defects that lead to bacterial cell death. This review explores the recent advances in small-molecule inhibitors targeting the Lol system and examines the mechanisms of LolABCDE function, along with the structural and biochemical characteristics of its components. We also summarize the progress made in the discovery and optimization of inhibitors, including their modes of action, resistance mechanisms, and therapeutic potential. Despite significant progress, challenges, such as limited drug permeability and emerging resistance, continue to hinder therapeutic success. Overcoming these challenges necessitates strategies to enhance inhibitor selectivity and bypass the intrinsic defense mechanisms of gram-negative bacteria. This review aims to provide insights into the potential of targeting the Lol system as a novel strategy for combating antimicrobial resistance and developing effective therapies against gram-negative bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.